These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15916459)

  • 21. Cardiovascular risk management in clinical practice: the Midwest Heart Specialists experience.
    Kinn JW; Brown AS
    Am J Cardiol; 2002 Mar; 89(5A):23C-29C; discussion 30C. PubMed ID: 11900715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesterol drug lowers LDL-C levels but again fails to show clinical benefit.
    Mitka M
    JAMA; 2010 Jan; 303(3):211-2. PubMed ID: 20085945
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiovascular risk and statin use in the United States.
    Johansen ME; Green LA; Sen A; Kircher S; Richardson CR
    Ann Fam Med; 2014; 12(3):215-23. PubMed ID: 24821892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of hyperlipidemia in older adults.
    Alexander KP; Blazing MA; Rosenson RS; Hazard E; Aronow WS; Smith SC; Ohman EM
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):49-58. PubMed ID: 19124599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare.
    Hyun KK; Redfern J; Patel A; Peiris D; Brieger D; Sullivan D; Harris M; Usherwood T; MacMahon S; Lyford M; Woodward M
    Heart; 2017 Apr; 103(7):492-498. PubMed ID: 28249996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication-based versus target-based lipid management.
    Fazio S; Shapiro MD
    J Diabetes; 2018 Oct; 10(10):789-792. PubMed ID: 29962061
    [No Abstract]   [Full Text] [Related]  

  • 27. Patient and physician predictors of hyperlipidemia screening and statin prescription.
    Kannan S; Asch DA; Kurtzman GW; Honeywell S; Day SC; Patel MS
    Am J Manag Care; 2018 Aug; 24(8):e241-e248. PubMed ID: 30130024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study.
    Wei L; MacDonald TM; Watson AD; Murphy MJ
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):385-92. PubMed ID: 16998946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementing cardiovascular disease preventive care guidelines in general practice: an opportunity missed.
    Hespe CM; Campain A; Webster R; Patel A; Rychetnik L; Harris MF; Peiris DP
    Med J Aust; 2020 Oct; 213(7):327-328. PubMed ID: 32880959
    [No Abstract]   [Full Text] [Related]  

  • 30. Provider adherence to clinical guidelines related to lipid-lowering medications.
    Cohen SM; Kataoka-Yahiro M
    Mil Med; 2010 Feb; 175(2):122-6. PubMed ID: 20180482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomic impact evaluation of statin adherence in high-risk unselected post myocardial infarction population: an administrative database-guided analysis.
    Summaria F; Ciaralli F; Mustilli M; Sette A; Lanzillo C; Vasselli L
    Med Arch; 2013; 67(5):314-7. PubMed ID: 24601159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk management in type 2 diabetes of more than 10-year duration: Results of Polish ARETAEUS2-Grupa Study.
    Leśniak W; Bała MM; Płaczkiewicz-Jankowska E; Topór-Mądry R; Jankowski M; Sieradzki J; Banasiak W;
    Cardiol J; 2015; 22(2):150-9. PubMed ID: 25299503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [JUPITER study, more reason to give statins as preventive measure - commentary].
    Narkiewicz K
    Kardiol Pol; 2009 Mar; 67(3):346-7. PubMed ID: 19469067
    [No Abstract]   [Full Text] [Related]  

  • 34. Reducing CVD risk.
    Aranjo C
    Aust Fam Physician; 2008 Sep; 37(9):695. PubMed ID: 18837159
    [No Abstract]   [Full Text] [Related]  

  • 35. Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy.
    Tsang JL; Mendelsohn A; Tan MK; Hackam DG; Leiter LA; Fitchett D; Lin PJ; Grima E; Langer A; Goodman SG;
    Am J Cardiol; 2008 Nov; 102(9):1142-5. PubMed ID: 18940280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
    Nicholls SJ; Uno K; Kataoka Y
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1383-90. PubMed ID: 22059787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level.
    Roccatagliata D; Avanzini F; Monesi L; Caimi V; Lauri D; Longoni P; Marchioli R; Tombesi M; Tognoni G; Roncaglioni MC;
    Vasc Health Risk Manag; 2006; 2(4):507-14. PubMed ID: 17323606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Over-the-counter statins? Sorting out the issues.
    Hughes S
    J Cardiovasc Nurs; 2004; 19(6):430-1. PubMed ID: 15529067
    [No Abstract]   [Full Text] [Related]  

  • 40. A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention.
    Sauser K; Levine DA; Hayward RA
    Evid Based Med; 2015 Oct; 20(5):162-9. PubMed ID: 26173413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.